Nanovectors for anti-cancer drug delivery in the treatment of advanced pancreatic adenocarcinoma

Table 2 Selected nanomedicines studied in clinical trials for pancreatic adenocarcinoma

Nanomedicine	Nanoplatform	Status	Reference/trial information
Nanoplatin (NC-6004)	Polymeric nanoparticle (PEG-polyaspartate) of cisplatin	Phase III on going in advanced disease as 1st-line; 290 patients expected	NCT02043288; gemcitabine ± NC6004
EndoTAG-1	Cationic liposome encapsulated paclitaxel	Phase II (with gemcitabine vs gemcitabine) published in 2012	Löhr et al[56] 2012/NCT00377936
Genexol-PM	Methoxy-PEG-poly(D,L-lactide) based	Phase II monotherapy published in 2010	Saif et al[65] 2010/NCT00111904
	formulation of paclitaxel
Rexin-G	Pathotropic nanoparticle with cytocidal cyclin G1 construct	Phase I/II monotherapy published in 2010	Chawla et al[66] 2010/NCT00504998
Lipoplatin	Liposomal formulation of cisplatin	Phase I/II (with gemcitabine) published in 2006	Stathopoulos et al[67] 2006
Caelyx/Doxil	Liposomal formulation of doxorubicin	Phase II monotherapy published in 1995 and 2001	Schwartz et al[68] 1995; Halford et al[69] 2001